Business
Verrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial Capabilities
– Gerard DiGirolamo joins as Vice President, Sales,and Sheila Kennedy joins as Vice President, Marketing – – Extensive expertise and deep relationships in
About this update from Verrica Pharmaceuticals Inc.
[{"type":"text","content":"– Gerard DiGirolamo joins as Vice President, Sales,and Sheila Kennedy joins as Vice President, Marketing –\n – Extensive expertise and deep relationships in dermatology therapeutics will support potential launch of YCANTH™ for the treatment of molluscum contagiosum – WEST CHESTER, Pa., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced the appointment of two new Vice Presidents in its Commercial Operations group to support the potential launch, if approved, of YCANTH™ (cantharidin 0.7% topical solution), the Company’s investigational treatment for molluscum contagiosum (molluscum) for which an NDA is currently under review by the FDA, with a PDUFA goal date of July 13, 2020. Gerard DiGirolamo joins as Vice President, Sales, bringing substantial dermatology experience and demonstrated successes in launching brands in the category. Sheila Kennedy, a proven brand marketing leader who has also launched numerous products in the category, and maintains deep relationships in the dermatology community, has been appointed Vice President, Marketing. In his new role, Mr. DiGirolamo will be responsible for the strategic design, implementation, and leadership of Verrica’s entire sales organization. He will oversee recruiting and staffing of representatives, and build a field force to support the potential market introduction of YCANTH™. Ms. Kennedy will guide the product launch strategy, and lead the Company’s multi-channel marketing effort strategy, including Healthcare Professionals, Consumer, and Market Access programs. She will also cultivate a network of KOLs and HCPs on behalf of the Company. Both Mr. DiGirolamo and Ms. Kennedy will report to Joseph Bonaccorso, Verrica’s Chief Commercial Officer. “With the hiring of Gerard and Sheila, we gain even deeper expertise in the dermatology space, and increase our ability to engage providers in productive dialogue about how YCANTH™ may potentially be an important part of the molluscum treatment paradigm,” said Joseph Bonaccorso, Chief Commercial Officer of Verrica. “Our new colleagues will play critical roles in the potential commercial launch of YCANTH™, and with decades of combined dermatology sales and marketing experience...